tradingkey.logo

Cosmos Health Inc

COSM
查看詳細走勢圖
0.450USD
+0.010+2.23%
收盤 02/06, 16:00美東報價延遲15分鐘
14.33M總市值
虧損本益比TTM

Cosmos Health Inc

0.450
+0.010+2.23%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+2.23%

5天

-6.43%

1月

-13.32%

6月

-43.64%

今年開始到現在

-9.74%

1年

-35.79%

查看詳細走勢圖

TradingKey Cosmos Health Inc股票評分

單位: USD 更新時間: 2026-02-06

操作建議

Cosmos Health Inc當前公司基本面數據相對穩定,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在藥品行業排名120/159位。機構持股佔比非常高,近一月多位分析師給出公司評級為。最高目標價為3.00。中期看,股價處於下降通道。近一個月,市場表現非常差,但基本面評分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Cosmos Health Inc評分

相關信息

行業排名
120 / 159
全市場排名
417 / 4521
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

Cosmos Health Inc亮點

亮點風險
Cosmos Health Inc. is a diversified, vertically integrated global healthcare company. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe, C-Sept and C-Scrub. Through its subsidiary Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. It also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and over-the-counter (OTC) medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the United Kingdom. It also has research and development (R&D) partnerships targeting health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of patented nutraceuticals, specialized root extracts, proprietary complex generics, and OTC products.
業績增長期
公司處於發展階段,最新年度總收入54.43M美元
估值低估
公司最新PE估值-0.59,處於3年歷史低位
先鋒集團持倉
明星投資者先鋒集團持倉,最新持倉235.74K股
活躍度增加
近期活躍度增加,過去20天平均換手率0.15

分析師目標

基於 0 分析師
--
評級
3.000
目標均價
+511.87%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Cosmos Health Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Cosmos Health Inc簡介

Cosmos Health Inc. is a diversified, vertically integrated global healthcare company. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe, C-Sept and C-Scrub. Through its subsidiary Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. It also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and over-the-counter (OTC) medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the United Kingdom. It also has research and development (R&D) partnerships targeting health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of patented nutraceuticals, specialized root extracts, proprietary complex generics, and OTC products.
公司代碼COSM
公司Cosmos Health Inc
CEOSiokas (Grigorios)
網址https://www.cosmosholdingsinc.com/
KeyAI